

VITEK® 2

Susceptibility Cards for Gram Negative Bacilli



Class	Antibiotic	MIC Calling Range	GN66	GN67	GN68	GN69	GN70	GN71	GN72	GN73	GN74	GN75	GN76	GN77	GN79	GN80	GN81	GN82	GN83	GN84	GN86	GN87	GN90	GN91	GN92	GN93	*XN06
			413398	413399	413431	413400	413401	413402	413403	413404	413941	413432	413433	413434	413436	413437	413438	413439	413440	413410	413942	413943	414779	414780	414963	414985	413944
Aminopenicillin / inhibitor combination	Amoxicillin / Clavulanic Acid	2/1 - 32/16																									
	Ampicillin	2 - 32																									
	Ampicillin / Sulbactam	2/1 - 32/16																									
Ureidopenicillin / inhibitor combinations	Piperacillin	4 - 128																									
	Piperacillin / Tazobactam	4/4 - 128/4																									
	Ticarcillin	8 - 128																									
	Ticarcillin / Clavulanic Acid	8/2 - 128/2																									
Cephalosporin I	Cefalotin	2 - 64																									
	Cefazolin	4 - 64																									
Cephalosporin II / Cephamycin	Cefotetan	4 - 64																									
	Cefoxitin	4 - 64																									
	Cefuroxime	1 - 64																									
Cephalosporin III / IV	Cefepime	1 - 64																									
	Cefotaxime	1 - 64																									
	Cefpodoxime	0.25 - 8																									
	Ceftazidime	1 - 64																									
	Ceftizoxime	1 - 64																									
	Ceftriaxone	1 - 64																									
Monobactam	Aztreonam	1 - 64																									
ESBL	ESBL Confirmation Test	+/-																									
Carbapenem	Doripenem	0.12 - 8																									
	Ertapenem	0.5 - 8																									
	Imipenem	0.25 - 16																									
	Meropenem	0.25 - 16																									
Aminoglycoside	Amikacin	2 - 64																									
	Gentamicin	1 - 16																									
	Tobramycin	1 - 16																									
Fluroquinolone	Ciprofloxacin	0.25 - 4																									
	Levofloxacin	0.12 - 8																									
	Moxifloxacin	0.25 - 8																									
	Norfloxacin	16 - 512																									
Tetracyclines	Tetracycline	1 - 16																									
	Tigecycline	0.5 - 8																									
Miscellaneous	Nalidixic Acid	2 - 32																									
	Nitrofurantoin	16 - 512																									
	Trimethoprim / Sulfamethoxazole	20 (1/19) - 320 (16/304)																									

Susceptibility Cards for Gram Positive Cocci

(*Staphylococcus spp.*, *Enterococcus spp.* and *S. agalactiae*)

Antibiotic	MIC Calling Range	GP67	GP72	GP75	GP78	FDA Indications for USE
		22226	410770	415670	421051	
Ampicillin						
<i>Enterococcus spp.</i>	2 - 32					<i>Enterococcus spp.</i>
<i>S. agalactiae</i>	0.25 - 16					<i>S. agalactiae</i>
Ampicillin/Sulbactam	2/1 - 32/16					<i>Staphylococcus spp.</i>
Benzylpenicillin						
<i>Enterococcus spp.</i>	0.12 - 64					<i>Enterococcus spp.</i>
<i>Staphylococcus spp.</i>	0.03 - 0.5					<i>Staphylococcus spp.</i>
<i>S. agalactiae</i>	0.12 - 64					<i>S. agalactiae</i>
Cefoxitin Screen	NEG - POS					<i>Staphylococcus spp.</i>
Ceftaroline	0.06-4					MRSA**, MSSA**
Chloramphenicol	4 - 64					<i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i> , <i>S. agalactiae</i>
Ciprofloxacin	0.5 - 8					<i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i>
Clindamycin	0.25 - 8					<i>Staphylococcus spp.</i> , <i>S. agalactiae</i>
Clindamycin	0.125 - 4					MSSA**, MSSE**
Daptomycin (NS)	0.12 - 8					<i>S. aureus</i> , VSEfaeca**
Doxycycline	0.5 - 16					<i>S. aureus</i>
Erythromycin	0.25 - 8					<i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i> , <i>S. agalactiae</i>
Gentamicin	0.5 - 16					<i>Staphylococcus spp.</i>
Gentamicin High Level (synergy)	S - R					<i>Enterococcus spp.</i>
Inducible Clindamycin Resistance	NEG - POS					<i>Staphylococcus spp.</i>
Levofloxacin	0.12 - 8					<i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i> , <i>S. agalactiae</i>
Linezolid	0.5 - 8					<i>S. agalactiae</i> , <i>E. faecalis</i> , <i>E. faecium</i> , <i>S. aureus</i> , <i>S. epidermidis</i> , <i>S. haemolyticus</i>
Minocycline	0.5 - 16					<i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i>
Moxifloxacin	0.25 - 8					MSSA**
Nitrofurantoin	16 - 512					<i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i>
Oxacillin	0.25 - 4					<i>Staphylococcus spp.</i>
Quinupristin/Dalfopristin	0.25 - 16					MSSA**, <i>S. epidermidis</i> , VREF**, <i>S. agalactiae</i>
Rifampicin	0.5 - 32					<i>Staphylococcus spp.</i>
Streptomycin High Level (synergy)	S - R					<i>Enterococcus spp.</i>
Tetracycline	1 - 16					<i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i> , <i>S. agalactiae</i>
Tigecycline (NS)	0.12 - 2					<i>E. faecalis</i> , <i>E. faecium</i> , <i>S. aureus</i> , <i>S. epidermidis</i> , <i>S. haemolyticus</i> , <i>S. agalactiae</i> , <i>E. casseliflavus</i>
Trimethoprim/Sulfamethoxazole (c)	10 (0.5/9.5) 320 (16/304)					<i>S. aureus</i>
Vancomycin	0.5 - 32					<i>Enterococcus spp.</i> , <i>Staphylococcus spp.</i> , <i>S. agalactiae</i>

Notes
NS = The current absence of resistant isolates precludes defining any results other than susceptible. Isolates yielding MIC results suggestive of Nonsusceptible category should be submitted to a reference laboratory for further testing., ***VSEfaeca** = *E. faecalis* (vancomycin susceptible strains), ***MSSA** = Methicillin-susceptible *S. aureus*, ***VREF** = Vancomycin-resistant *E. faecium*, **c** = Category agreement was established at the time of FDA clearance. Essential agreement was not established since test contains less than five discrete dilutions. ***MRSA** = Methicillin-resistant *S. aureus*, ***MSSE** = Methicillin-susceptible *S. aureus*.

AST-GP74 414971 *S. pneumoniae* Susceptibility Cards

Antibiotic	MIC Calling Range	FDA Indications for USE
Amoxicillin	0.06 - 8	<i>S. pneumoniae</i>
Benzylpenicillin	0.06 - 8	SP(P&M)**
Cefotaxime	0.06 - 4	<i>S. pneumoniae</i>
Ceftriaxone	0.06 - 4	<i>S. pneumoniae</i>
Chloramphenicol	2 - 32	<i>S. pneumoniae</i>
Ertapenem	0.5 - 8	Spn except P(R)**
Erythromycin (c)	0.25 - 1	<i>S. pneumoniae</i>
Levofloxacin	0.5 - 8	<i>S. pneumoniae</i>
Linezolid	2 - 4	<i>S. pneumoniae</i>
Meropenem	0.06 - 4	<i>S. pneumoniae</i>
Moxifloxacin	0.25 - 4	<i>S. pneumoniae</i>
Ofloxacin	1 - 8	<i>S. pneumoniae</i>
Telithromycin	0.25 - 4	<i>S. pneumoniae</i>
Tetracyclines	1 - 16	<i>S. pneumoniae</i>
Trimethoprim / Sulfamethoxazole	10 (0.5/9.5) - 320 (16/304)	<i>S. pneumoniae</i>
Vancomycin	1 - 2	<i>S. pneumoniae</i>

Notes
c = Category agreement was established at the time of FDA clearance. Essential agreement was not established since test contains less than five discrete dilutions.
****SP(P&M)** = *S. pneumoniae* (pneumonia and meningitis), ****Spn except P(R)** = *S. pneumoniae* (excluding penicillin-resistant strains)

AST-ST02 420915 *Streptococcus* Susceptibility Cards

Antimicrobial	MIC Calling Range	FDA Indications for USE
Ampicillin (NS2)	0.25 - 16	grpBetaHS**, grpVIR**
Benzylpenicillin (NS2)	0.06 - 8	grpC/G**, <i>S. pyogenes</i> , <i>S. agalactiae</i> , <i>S. pneumoniae</i> , grpVIR**
Cefotaxime	0.12 - 8	<i>S. pneumoniae</i> , SpyA**, <i>Streptococcus spp.</i>
Ceftriaxone (NS2)	0.12 - 8	grpVIR**, <i>S. agalactiae</i> , <i>S. pneumoniae</i> , <i>S. pyogenes</i>
Clindamycin (c)	0.25 - 1	SP(Pen(S))**, <i>S. pyogenes</i> , <i>S. agalactiae</i> , <i>S. mitis</i> , <i>S. oralis</i>
Erythromycin	0.12 - 8	<i>S. pneumoniae</i> , <i>S. pyogenes</i> , grpVIR**
Inducible Clindamycin Resistance <i>S. agalactiae</i> , <i>S. pyogenes</i>	NEG - POS	<i>S. agalactiae</i> , <i>S. pyogenes</i>
Levofloxacin	0.25 - 16	SP+MDRSP**, <i>S. pyogenes</i> , grpC/F**, grpG**, <i>S. agalactiae</i> , grpVIR**, <i>S. milleri</i>
Linezolid (NS2)	2 - 8	SP+MDRSP**, <i>S. agalactiae</i> , <i>S. pyogenes</i>
Moxifloxacin	0.06 - 4	<i>S. anginosus</i> , <i>S. constellatus</i> , SP+MDRSP**, <i>S. pyogenes</i> , <i>S. agalactiae</i> , grpVIR**
Tetracyclines	0.25 - 16	<i>S. pneumoniae</i> , <i>S. pyogenes</i> , grpVIR**
Tigecycline (NS)	0.06 - 1	SP(Pen(S))** <i>S. anginosus</i> grp. (includes <i>S. anginosus</i> , <i>S. intermedius</i> , and <i>S. constellatus</i>), <i>S. agalactiae</i> , <i>S. pyogenes</i>
Trimethoprim/Sulfamethoxazole (c)	10 (0.5/9.5) 320 (16/304)	<i>S. pneumoniae</i> .
Vancomycin (NS)	0.12 - 8	grpVIR**, <i>S. pyogenes</i> , <i>S. agalactiae</i>

Notes
NS2 = Beta-hemolytic Streptococci. The current absence of resistant isolates precludes defining any results other than susceptible. Isolates yielding MIC results suggestive of Nonsusceptible category should be submitted to a reference laboratory for further testing. ***grpBetaHS** = Beta-hemolytic group Streptococcus species, ***grpVIR** = Viridans group Streptococcus, ***grpC/G** = Beta-hemolytic Streptococcus groups C and G, ***SpyA** = *S. pyogenes* (Group A beta-hemolytic streptococci), **c** = Category agreement was established at the time of FDA clearance. Essential agreement was not established since test contains less than five discrete dilutions. ***SP(Pen(S))** = *S. pneumoniae* (penicillin-susceptible strains) ***SP+MDRSP** = *S. pneumoniae* (including multi-drug resistant strains (MDRSP)) ***grpC/F** = Beta-hemolytic Streptococcus groups C and F ***grpG** = Beta-hemolytic Streptococcus group G. **NS** = The current absence of resistant isolates precludes defining any results other than susceptible. Isolates yielding MIC results suggestive of Nonsusceptible category should be submitted to a reference laboratory for further testing.

To order please visit: www.biomerieuxDIRECT.com